Data from several studies suggested that EGFR and KRAS mutations were associated with poor prognosis of NSCLC patients.[10,11] EGFR-TKs show greater treatment benefits for NSCLC patients with EGFR mutation rather than KRAS mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.